Abstract
Treatment of patients with sepsis with monoclonal antibodies against lipopolysaccharide, tumour necrosis factor or treatment with soluble TNF-receptors or interleukin-1 receptor antagonist have not had any effect on mortality. Treatment with intravenous polyclonal nonspecific immunoglobulin has been shown to have beneficial efficacy on mortality. However, the number of patients included in the latter treatment studies are limited, the patients studied are heterogeneous and do not allow to conclude that sepsis patients should be routinely treated with immunoglobulins.
Bidragets oversatte titel | Non-antibiotic treatment of sepsis |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 162 |
Udgave nummer | 20 |
Sider (fra-til) | 2872-5 |
Antal sider | 4 |
ISSN | 0041-5782 |
Status | Udgivet - 15 maj 2000 |
Udgivet eksternt | Ja |
Emneord
- Animals
- Antibodies, Monoclonal/therapeutic use
- Clinical Trials as Topic
- Humans
- Immunoglobulins, Intravenous/therapeutic use
- Interleukin-1/immunology
- Receptors, Interleukin-1/antagonists & inhibitors
- Receptors, Tumor Necrosis Factor/antagonists & inhibitors
- Sepsis/drug therapy
- Tumor Necrosis Factor-alpha/immunology